---
document_datetime: 2023-09-21 18:08:54
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/soliris-epar-all-authorised-presentations_en.pdf
document_name: soliris-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7656137
conversion_datetime: 2025-12-24 19:15:23.39076
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| EU Number       | Invented name   | Strength   | Pharmaceutical   | Route of        | Packaging    | Content (concentration)   | Package size   |
|-----------------|-----------------|------------|------------------|-----------------|--------------|---------------------------|----------------|
|                 |                 |            | Form             | administration  |              |                           |                |
| EU/1/07/393/001 | Soliris         | 300 mg     | Concentrate for  | Intravenous use | Vial (glass) | 30 ml (10 mg/ml)          | 1 vial         |